June 19, 2014—The Health Resources and Services Administration acted “wholly at odds” with a federal district judge’s orders when it announced yesterday that it stands by its interpretation of the 340B orphan drug exclusion, brand-name drugmakers argued in papers filed with the judge late on June 18.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register.
Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)